Abstract
The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec®) against controlled release (CR) salbutamol (Volmax®) in the treatment of nocturnal asthma.
One hundred and fifty two asthmatic patients aged 17–78 years, using ≥800 μg/day of an inhaled steroid, with nocturnal asthma symptoms, openly received three weeks of bambuterol 20 mg nocte and three weeks of salbutamol CR 8 mg b.i.d. in a randomised, cross over sequence.
Both bambuterol and salbutamol CR treatment produced a significant 63% decrease in the severity of baseline nocturnal asthma symptoms. This improved control of nocturnal asthma was reflected by significant improvements in baseline lung function. Both the severity and number of days of tremor during the first week of treatment was significantly lower with bambuterol than with salbutamol CR. Patients considered bambuterol to cause less shakiness and treatment preference was bambuterol 49%, salbutamol CR 36%, no preference 15%. The predominant reason for patient treatment preference was control of asthma symptoms, however a significant sub-group of patients (27%) chose bambuterol because of fewer adverse effects compared to 11% chosing salbutamol CR. Fifty six percent of patients preferred taking their medication once-daily and 7% preferred twice-daily.
This study shows that both bambuterol and salbutamol CR are equally effective treatments for nocturnal asthma in patients already receiving inhaled steroid. The most important factor in terms of patient treatment acceptability appears to be control of symptoms. Sub-groups of patients may chose bambuterol due to its better adverse effect profile and once-daily regimen.
Similar content being viewed by others
References
British Thoracic Society, British Paediatric Association, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign, Royal College of General Practitioners, et al (1993) Guidelines for management of asthma in adults: I-Chronic persistent asthma. Thorax 48 [Suppl]: S1-S24
Lipworth BJ, Clark RA, Dhillon DP, Palmer JBD, McDevitt DG (1990) Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma. Eur J Clin Pharmacol 39: 281–285
Viskum K, Dahl R, Korsgaard J, Svendsun U (1988) A comparison of controlled release salbutamol tablets (Volmax®) and sustained release terbutaline tablets (Bricanyl SA®). Eur Resp J 1 [Suppl 2]: 305 S
Smolensky MH, DÁlonzo GE (1991) Administration-time dependency of the kinetics and effect of once-daily 20 mg dosing of bambuterol versus placebo in asthma patients. Eur Resp J 4 [Suppl 14]: 555 S
Olsson OAT, Svensson LA (1984) New terbutaline ester prodrugs with long effect duration. Pharm Res 1: 19–23
Fugleholm AM, Ibsen TB, Laxmyr L, Svendson UB (1993) Therapeutic equivalence between bambuterol 10 mg once daily and terbutaline controlled releasing 5 mg twice daily in mild to moderate asthma. Eur Res J 6: 1474–1478
Larsén K, Schmekel B (1993) Tremor in healthy volunteers after bambuterol and terbutaline CR tablets. Eur J Clin Pharmacol 45: 303–305
Petrie GR, Chookang J, Hassan WV, Morrison JF, O'Reilly JF, Pearson SB, et al (1993) Bambuterol: effective in nocturnal asthma. Resp Med 84: 581–585
Hills M, Armitage P (1979) The two-period cross-over clinical trial. Br J Clin Pharmacol 8: 7–20
Svedmyr NV, Larssen SA, Thiringer GK (1976) Development of “resistance” in beta-adrenergic receptors of asthmatic patients. Chest 69: 479–483
Ahrens RC (1990) Skeletal muscle tremor and the influence of adrenergic drugs. J Asthma 27: 11–20
Ayd FJ (1972) Once-a-day neuroleptic and tricyclic anti-depressant therapy. Int Drug Ther Newsletter 7: 33
Cramer JA, Mattson RH, Prevey ML, Scheyer MDS, Ouellette RN (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 22: 3273–3277
Eisen SA, Miller DK, Woodward RS, Spitznagel E, Pryzbeck TR (1990) The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150: 1881–1884
Campbell LM, Watson DG, Venables TL, Taylor MD, Richardson PDI (1991) Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res 2: 111–122
Welch MJ, Kemp JP, Ostrom NK, Orgel HA, Meltzer EO, Romero L, et al (1993) A comparative study of a new once-a-day theophylline preparation with Theo-Dur given twice daily. J Asthma 30: 211–218
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gunn, S.D., Ayres, J.G., Follows, R.M.A. et al. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. Eur J Clin Pharmacol 48, 23–28 (1995). https://doi.org/10.1007/BF00202167
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00202167